

## CEO Statement

In July 2020, 2cureX carried out a directed issue of 1,213,000 units, consisting of two (2) shares and one (1) warrant of series TO1. At the same time, additional 1,242,000 warrants of series TO1 (same series as in the directed issue) were granted free of charge to all existing shareholders in 2cureX at a ratio of one (1) warrant of series TO1 for every ten (10) shares held, to compensate for the dilution incurred in the directed issue. The process was conducted with support from Mangold Fondkommission AB.

The funds raised in that operation supported 2cureX preparation for the CE marking and launch of the first IndiTreat® test, which was introduced to the market at the ESMO (European Society of Medical Oncology) conference in October.

The exercise period for these 2,455,000 warrants will run from 26 April to 7 May 2021.

2cureX is leading the way to make Functional Testing part of standard clinical practice in Oncology using a unique 3D micro-tumor technology. A Functional Test is a drug sensitivity / drug resistance test conducted in vitro on cells derived from an individual patient tumor. Through these tests, oncologists can predict which drugs will work or not work on a specific patient, prior to starting the treatment. Using Functional Tests as a standard of care would not only improve patient's outcomes but also avoid costs of unnecessary treatments for healthcare systems.

Since its foundation in 2007, 2cureX has been developing and perfecting the technology to make oncology Functional Tests faster and more accurate, suitable for its use in clinical practice. Through our proprietary technology, which is protected by a portfolio of patents in the major markets, our IndiTreat® tests generate hundreds of 3D micro-tumors replicating the characteristics of the original patient tumor. These 3D micro-tumors are then exposed to extensive panels of drugs and drug combinations to accurately predict response or resistance, fulfilling the promise of personalized medicine.

IndiTreat® is a family of tests that will cover multiple cancer entities and several indications within each of them. Our first product in the market supports 3rd line treatment decision-making in metastatic colorectal

cancer. Strong evidence for the clinical use of this test comes from the recently finished TICC clinical trial (NCT03251612) which fulfilled its primary endpoint, defined as showing improvement in 8-week Progression Free Survival. We expect the full disclosure of these results at the ASCO (American Society of Clinical Oncology) conference held June 4th to 8th to further accelerate the uptake of IndiTreat®.

While we are conducting all the market access activities required to get the test reimbursed and included in the clinical guidelines at the different European countries, early adopters across Europe have already shown interest in using it, and we are establishing early access agreements with them that will lead to the first sales in the coming months.

I would like to encourage all warrant holders to exercise their rights as this will provide additional funding to speed up the activities described above, consolidating IndiTreat® as the first Functional Test in routine clinical use and 2cureX as the leading company in this new and promising space.

Thanks to all our shareholders for their continued support.

**Fernando Andreu**


CEO



## Terms and conditions

TERMS	For each one (1) warrant of series TO1, the holder can subscribe for one (1) new share in 2cureX
SUBSCRIPTION PRICE	SEK 13.22 per share
SUBSCRIPTION PERIOD	26 April 2021 to 7 May 2021
LAST DAY OF TRADING	5 May 2021
PAYMENT	Through simultaneous payment in cash

## Subscribing with warrants



*Are you a directly-registered warrant holder or do you have your warrants with a nominee?*

## You have a vp-account (i.e. directly registered)

The warrant holders who have TO1 in a VP-account subscribe directly via the registration form to Mangold ([www.mangold.se/aktuella-emissioner](http://www.mangold.se/aktuella-emissioner)). Registration is sent via email to [emissioner@mangold.se](mailto:emissioner@mangold.se) or by post according to instructions on the registration form.

The subscription proceed must be available for Mangold at latest 7 May 2021

## Nominee-registered warrant holder

Subscription for nominee-registered warrant holders takes place in accordance with instructions from the respective nominee. Note that the nominees need your notification of the use of TO1 in time before the end of the subscription period.

Payment according to instructions from nominee

If you are uncertain about whether your warrants are directly-registered or nominee-registered, contact the institution where you have your holdings.

PLEASE NOTE THAT IF WARRANTS ARE NOT SOLD AT LATEST MAY 5 2021, ALTERNATIVELY SUBSCRIBED AT LATEST 7 MAY 2021, THEY EXPIRE WORTHLESS. FOR YOUR WARRANTS NOT TO EXPIRE, YOU ARE REQUIRED TO ACTIVELY SUBSCRIBE YOUR WARRANTS, ALTERNATIVELY SELL THE WARRANTS WITHIN ABOVE MENTIONED PERIODS.